$3080 | SAVE $420 | Single User
$6160 | SAVE $840 | Site License
$9240 | SAVE $1,260 | Enterprise License

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017
[Report Updated: 10-10-2017]

Published by Global Markets Direct: 10 Oct 2017 | 139648 | In Stock
Related Topics: Diabetes , Hypercholesterolemia , Immunology , Infectious Disease , Steatohepatitis , Vascular

Introduction

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017

Summary

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) pipeline Target constitutes close to 28 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The latest report Proprotein Convertase SubtilisinKexin Type 9 - Pipeline Review, H2 2017, outlays comprehensive information on the Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme encoded by the PCSK9 gene. It is a crucial player in the regulation of plasma cholesterol homeostasis. It binds to low-density lipid receptor family members. It acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. It prevents the recycling of LDLR from endosomes to the cell surface or directs it to lysosomes for degradation. It induces ubiquitination of LDLR leading to its subsequent degradation. It inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 4, 3, 8, 6 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Cardiovascular, Gastrointestinal, Immunology, Infectious Disease and Oncology which include indications Hypercholesterolemia, Hyperlipidemia, Atherosclerosis, Cardiovascular Disease, Homozygous Familial Hypercholesterolemia (HoFH), Non-Alcoholic Steatohepatitis (NASH), Type 2 Diabetes, Bacterial Sepsis, Hypertriglyceridemia, Inflammation, Liver Diseases, Metabolic Syndrome, Non Alcoholic Fatty Liver Disease (NAFLD) and Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD).

Furthermore, this report also reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)

- The report reviews Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics and enlists all their major and minor projects

- The report assesses Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017 [Report Updated: 10-10-2017]

  • Table of Contents

    Table of Contents 2

    List of Tables 6

    List of Figures 6

    Introduction 7

    Global Markets Direct Report Coverage 7

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Overview 8

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Development 9

    Products under Development by Stage of Development 9

    Products under Development by Therapy Area 10

    Products under Development by Indication 11

    Products under Development by Companies 12

    Products under Development by Universities/Institutes 17

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Therapeutics Assessment 19

    Assessment by Mechanism of Action 19

    Assessment by Route of Administration 20

    Assessment by Molecule Type 22

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Companies Involved in Therapeutics Development 24

    AFFiRiS AG 24

    Betagenon AB 24

    Bioleaders Corp 25

    BioLingus AG 25

    Catabasis Pharmaceuticals Inc 25

    Dicerna Pharmaceuticals Inc 26

    Eli Lilly and Co 26

    Ensemble Therapeutics Corp 27

    Kowa Co Ltd 27

    Novartis AG 27

    Pfizer Inc 28

    Regeneron Pharmaceuticals Inc 28

    Serometrix LLC 29

    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 29

    The Medicines Company 30

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Drug Profiles 31

    AK-102 - Drug Profile 31

    Product Description 31

    Mechanism Of Action 31

    R&D Progress 31

    alirocumab - Drug Profile 32

    Product Description 32

    Mechanism Of Action 32

    R&D Progress 32

    Antisense Oligonucleotide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 44

    Product Description 44

    Mechanism Of Action 44

    R&D Progress 44

    Antisense RNAi Oligonucleotide to Inhibit PCSK-9 for Hypercholesterolemia - Drug Profile 45

    Product Description 45

    Mechanism Of Action 45

    R&D Progress 45

    AT-04A - Drug Profile 46

    Product Description 46

    Mechanism Of Action 46

    R&D Progress 46

    AT-06A - Drug Profile 47

    Product Description 47

    Mechanism Of Action 47

    R&D Progress 47

    BLSM-201 - Drug Profile 48

    Product Description 48

    Mechanism Of Action 48

    R&D Progress 48

    CAT-2000 Series - Drug Profile 49

    Product Description 49

    Mechanism Of Action 49

    R&D Progress 49

    CVI-LM001 - Drug Profile 50

    Product Description 50

    Mechanism Of Action 50

    R&D Progress 50

    DCRPCSK-9 - Drug Profile 51

    Product Description 51

    Mechanism Of Action 51

    R&D Progress 51

    Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 52

    Product Description 52

    Mechanism Of Action 52

    R&D Progress 52

    inclisiran - Drug Profile 53

    Product Description 53

    Mechanism Of Action 53

    R&D Progress 53

    JS-002 - Drug Profile 59

    Product Description 59

    Mechanism Of Action 59

    R&D Progress 59

    K-312 - Drug Profile 60

    Product Description 60

    Mechanism Of Action 60

    R&D Progress 60

    lodelcizumab - Drug Profile 61

    Product Description 61

    Mechanism Of Action 61

    R&D Progress 61

    LY-3015014 - Drug Profile 62

    Product Description 62

    Mechanism Of Action 62

    R&D Progress 62

    Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 63

    Product Description 63

    Mechanism Of Action 63

    R&D Progress 63

    Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 64

    Product Description 64

    Mechanism Of Action 64

    R&D Progress 64

    O-304 - Drug Profile 65

    Product Description 65

    Mechanism Of Action 65

    R&D Progress 65

    PF-06446846 - Drug Profile 67

    Product Description 67

    Mechanism Of Action 67

    R&D Progress 67

    Recombinant Protein to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 68

    Product Description 68

    Mechanism Of Action 68

    R&D Progress 68

    Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 70

    Product Description 70

    Mechanism Of Action 70

    R&D Progress 70

    Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 71

    Product Description 71

    Mechanism Of Action 71

    R&D Progress 71

    Small Molecules to Inhibit PCSK9 for Cardiovascular Disease - Drug Profile 72

    Product Description 72

    Mechanism Of Action 72

    R&D Progress 72

    Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 73

    Product Description 73

    Mechanism Of Action 73

    R&D Progress 73

    SX-PCK9 - Drug Profile 74

    Product Description 74

    Mechanism Of Action 74

    R&D Progress 74

    Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile 75

    Product Description 75

    Mechanism Of Action 75

    R&D Progress 75

    Vaccine to Target PCSK9 for Hypercholesterolemia - Drug Profile 76

    Product Description 76

    Mechanism Of Action 76

    R&D Progress 76

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Dormant Products 77

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Discontinued Products 79

    Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Product Development Milestones 80

    Featured News & Press Releases 80

    Aug 28, 2017: New, One-Year Data from ORION-1 Phase II Study of Inclisiran Extends Excellent Long-Term Efficacy and Safety Profile, Affirming Dose for Phase III Trials 80

    Aug 25, 2017: Regeneron and Sanofi to Present New Analyses from Praluent Injection Trials at the ESC Congress 2017 82

    Jun 11, 2017: Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes 82

    Jun 11, 2017: Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent (alirocumab) in Individuals with Diabetes and Hypercholesterolemia 84

    Apr 26, 2017: The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran 86

    Apr 25, 2017: Regeneron And Sanofi Announce FDA Approval Of A New Once-Monthly Dosing Option For Praluent (Alirocumab) Injection 87

    Mar 17, 2017: The Medicines Company and Alnylam Pharmaceuticals Report Positive Final Results from ORION-1 Phase II Study of Inclisiran 88

    Mar 14, 2017: The Medicines Company to Webcast Presentation of ORION-1 Phase II Study of Inclisiran at ACC.17 89

    Mar 07, 2017: Regeneron and Sanofi to Present New Phase 3 Praluent (alirocumab) Injection Clinical Trial Analyses at ACC.17 Scientific Sessions 89

    Feb 08, 2017: Appeals Court Grants Stay of Permanent Injunction for Praluent (alirocumab) During Appeals Process 91

    Jan 25, 2017: The Medicines Company to Present Results from ORION-1 Phase 2 Study of Inclisiran at the American College of Cardiology’s 66th Annual Scientific Session 91

    Jan 13, 2017: Sanofi and Regeneron File Notice of Appeal and Motion to Stay (Suspend) Injunction with Federal Circuit Court of Appeals in Patent Case Regarding Praluent (alirocumab) Injection 92

    Jan 09, 2017: Amgen Statement on January 9, 2017, U.S. District Court Decision 92

    Jan 08, 2017: The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran 92

    Jan 05, 2017: Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent (alirocumab) Injection 93

    Appendix 94

    Methodology 94

    Coverage 94

    Secondary Research 94

    Primary Research 94

    Expert Panel Validation 94

    Contact Us 94

    Disclaimer 95

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

139648 | GMDHC1038TDB

Number of Pages

95

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2018
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
23 Oct 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H1 2018
Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated...
24 Apr 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insight, 2018
“Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2018” report by...
14 Feb 2018 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017
DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor-Mechanism of action...
01 Sep 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors-Pipeline Insights,...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Proprotein Convertase Subtilisin/Kexin Type 9 (Proprotein Convertase 9 or Neural Apoptosis Regulated Convertase 1 or Subtilisin/Kexin Like Protease PC9 or PCSK9 or EC 3.4.21.) - Pipeline Review, H2 2017 [Report Updated: 10-10-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...